Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Mar 30;10(11):4900-4902.
doi: 10.7150/thno.44568. eCollection 2020.

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy

Finn Edler von Eyben  1 , Harshad R Kulkarni  2 , Richard P Baum  2
Affiliations
Editorial

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy

Finn Edler von Eyben et al. Theranostics. .

Abstract

PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with 177Lu PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.

Keywords: 177Lutetium [177Lu]-PSMA radioligand therapy; overall survival; prostate specific membrane antigen; prostatic neoplasms; restaging.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Kaplan-Meier plot of overall survival for patients with lymph node metastases (LNM) (site 1), LNM with one or two bone metastases, (site 2), bone metastases (site 3), lung metastases (site 4), and liver metastases (site 5).
See this image and copyright information in PMC

Comment on

References

    1. Kessel K, Seifert R, Schafers M, Weckesser M, Schlack K, Boegemann M. et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617. Theranostics. 2019;9:4841–8. - PMC - PubMed
    1. Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C. et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8:103108–16. - PMC - PubMed
    1. Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T. et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019;75:920–6. - PubMed
    1. Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J. et al. Predicors of Overall and Disease free survival in Metastatic Castration resistant Prostate Cancer Patients Receiving (225)Ac-PSMA-617 Radioligand therapy. J Nucl Med. 2020;61:62–9. - PubMed
    1. Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M. et al. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. Clin Nucl Med. 2020;45:19–31. - PubMed